Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Author:
Funder
Colombia Ministerio de Ciencia Tecnologia e Innovacion
Publisher
Elsevier BV
Reference226 articles.
1. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020
2. Human coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae);Liu,2021
3. An overview of literature on COVID-19, MERS and SARS: using text mining and latent Dirichlet allocation;Cheng;J. Inf. Sci.,2022
4. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population;Lau;Nat. Med.,2023
5. The WHO has declared the end of pandemic phase of COVID‐19: way to come back in the normal life;Sarker;Health Sci Rep,2023
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies;MedComm;2024-07-29
2. From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2;Vaccines;2024-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3